U.S. Food and Drug Administration approved Farxiga (dapagliflozin) for global congestive heart failure drugs market
Robust
pipeline of drugs under development for congestive heart failure is propelling
the growth of the congestive heart failure drugs market. Moreover, the growing
approval of new drugs from the Food and Drug Administration (FDA) is again
expected to augment the growth of the congestive heart failure drugs market.
For instance, in February 2021, Novartis announced that the US Food and Drug
Administration (FDA) has approved the following expanded indication for
Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death
and hospitalization for heart failure in adult patients with chronic heart
failure1.
On
other hand, lack of awareness and diagnosis rate for the disease such as
hypertension which is a major cause of heart failure is acting as a restraint
in the global congestive
heart failure drugs market. According to a study published in NCBI in
2013, only 49% of patients suffering from hypertension were aware of the
diagnosis in high-income countries, and this percentage (i.e. 40.8%) was even
lower in low-income countries
North
America is expected to gain significant growth over the forecast period and
this is attributed to the high prevalence rate of heart disease and also the
continuous launch of new products in the region. According to the U.S.
Department of Health & Human Services, about 6.2 million adults in the
United States have heart failure. In 2018, heart failure was mentioned on
379,800 death certificates (13.4%).
1. In May 2020, the U.S. Food and Drug Administration
approved Farxiga (dapagliflozin) oral tablets for adults with heart failure
with reduced ejection fraction to reduce the risk of cardiovascular death and
hospitalization for heart failure.
2. In January 2021, Merck & Co. and Bayer won Food
and Drug Administration approval for the heart failure drug Verquvo, one of the
few medicines Merck has recently brought through late-stage development
3. In May 2020, Amgen and Cytokinetics, Incorporated
announced that the U.S. Food and Drug Administration (FDA) has granted Fast
Track designation for omecamtiv mecarbil, being developed for the potential
treatment of chronic heart failure with reduced ejection fraction (HFrEF).
Congestive
Heart Failure (CHF) is a condition where the heart does not circulate enough
oxygenated blood throughout the body due to inadequate coronary blood flow.
Left-sided CHF describes a heart condition wherein the heart pump moves the
oxygen-rich blood into the right atrium, then to the left side, and back down
to the right ventricle. The right ventricle pumps most of the cardiovascular
force, so it is larger than the left ventricle and vital for proper cardiac
function. This allows the heart muscle to work harder, raising blood pressure,
which can cause fainting, dizziness, or shock if the ventricular pressure is
too high.

Comments
Post a Comment